NeuroSense Therapeutics Statistics
Share Statistics
NeuroSense Therapeutics has 23.99M
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding | 23.99M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Institutions (%) | 0.59% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 330 |
FTD / Avg. Volume | 3.66% |
Short Selling Information
Short Interest | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Valuation Ratios
PE Ratio | 0 |
Forward PE | n/a |
PS Ratio | 0 |
Forward PS | n/a |
PB Ratio | 0 |
P/FCF Ratio | 0 |
PEG Ratio | 0 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NeuroSense Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21,
with a Debt / Equity ratio of 0.03.
Current Ratio | 2.21 |
Quick Ratio | 2.21 |
Debt / Equity | 0.03 |
Debt / EBITDA | -0.01 |
Debt / FCF | -0.01 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | $-594,529.41 |
Employee Count | 17 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 6.84% in the
last 52 weeks. The beta is 1.34, so NeuroSense Therapeutics's
price volatility has been higher than the market average.
Beta | 1.34 |
52-Week Price Change | 6.84% |
50-Day Moving Average | 0.22 |
200-Day Moving Average | 0.25 |
Relative Strength Index (RSI) | 64.37 |
Average Volume (20 Days) | 9,013 |
Income Statement
Revenue | n/a |
Gross Profit | -97K |
Operating Income | -12.05M |
Net Income | -10.11M |
EBITDA | -10.63M |
EBIT | -10.73M |
Earnings Per Share (EPS) | -0.83 |
Full Income Statement Balance Sheet
The company has 3.38M in cash and 73K in
debt, giving a net cash position of 3.31M.
Cash & Cash Equivalents | 3.38M |
Total Debt | 73K |
Net Cash | 3.31M |
Retained Earnings | -36.66M |
Total Assets | n/a |
Working Capital | n/a |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -10.13M
and capital expenditures -3K, giving a free cash flow of -10.14M.
Operating Cash Flow | -10.13M |
Capital Expenditures | -3K |
Free Cash Flow | -10.14M |
FCF Per Share | 0 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |